Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

NCT01721876 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

666

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Placebo
DRUG: Volasertib
DRUG: Cytarabine

Sponsor

Boehringer Ingelheim